eMERGE Harvard Group

Rheumatology Auto-Immune characteristics

Dear,

To identify cases with auto-immune rheumatologic phenotye (for NT198) we request information about auto-antibody (whether it was tested and what the restults were) and drug information (whether it was prescribed) for each patients that is enrolled in eMERGE. We are requesting every mention of any of the expanded generic drugs.

Owner Phenotyping Groups:

Final

Type 2 Diabetes - PRS Evaluation

NOTE:

The following files were updated on 4/9/2021 so that the output of the #feature table in the eMERGE_IV_OMOP_T2DM_PRS_algorithm script matches the data dictionary.

Files:

T2DM_DD_Feature_Count_OMOP_2021049.csv
eMERGE_IV_OMOP_T2DM_PRS_algorithm_20210409.txt
eMERGE_IV_OMOP_T2DM_PRS_algorithm_20210409.zip

Owner Phenotyping Groups:

eMERGE Harvard Group

View Phenotyping Groups:

eMERGE Phenotype WG

Final

Type1 or Type 2 Diabetes Mellitus

Phenotyping algorithm for the identification of patients with type 1 or type 2 diabetes mellitus (DM) preoperatively using routinely available clinical data from electronic
health records.

View Phenotyping Groups:

American-Swiss Allergy Phenotyping Group

BioVU Phenotyping

Clostridium Difficile Colitis Phenotype Group

Denny’s Group at Vandy

eMERGE CCHMC Group

eMERGE CCHMC/BCH Group

eMERGE CHOP Group

eMERGE Columbia Group

eMERGE Geisinger Group

eMERGE GHC/University of Washington Group

eMERGE Harvard Group